The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival
Open accessAbstract
Purpose: Despite the fact that most gastroenteropancreatic neuroendocrine tumors (GEPNETs) are slow-growing, median overall survival (OS) in patients with liver metastases is 2 to 4 years. In metastatic disease, cytoreductive therapeutic options are limited. A relatively new therapy is peptide receptor radionuclide therapy with the radiolabeled somatostatin analog [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate. Here we report on the toxicity and efficacy of this treatment, performed in over 500 patients. Patients and Methods: Patients were treated up to a cumulative dose of 750 to 800 mCi (27.8-29.6 GBq), usually in four treatment cycles, with treatment intervals of 6 to 10 weeks. Toxicity analysis was done in 504 patients, and efficacy analysis in 310 patients. Results: Any hematologic toxicity grade 3 or 4 occurred after 3.6% of administrations. Serious adverse events that were likely attributable to the treatment were myelodysplastic syndrome in three patients, and temporary, nonfatal, liver toxicity in two patients. Complete and partial tumor remissions occurred in 2% and 28% of 310 GEPNET patients, respectively. Minor tumor response (decrease in size > 25% and < 50%) occurred in 16%. Median time to progression was 40 months. Median OS from start of treatment was 46 months, median OS from diagnosis was 128 months. Compared with historical controls, there was a survival benefit of 40 to 72 months from diagnosis. Conclusion: Treatment with [ 177 Lu-DOTA 0 ,Tyr 3 ]octreotate has few adverse effects. Tumor response rates and progression-free survival compare favorably to the limited number of alternative treatment modalities. Compared with historical controls, there is a benefit in OS from time of diagnosis of several years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A 5‐decade analysis of 13,715 carcinoid tumors
Modlin, I. M., Lye, K. D., & Kidd, M. (2003) · Cancer · doi:10.1002/cncr.11105 · Cited by 2,734
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Self-citationSouthwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P., Konijnenberg, M. W., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. L., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100574 · Cited by 471
Self-citationCarcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center
Janson, E. T., Holmberg, L., Stridsberg, M., Eriksson, B., Theodorsson, E., Wilander, E., & öberg, K. (1997) · Annals of Oncology · doi:10.1023/a:1008215730767 · Cited by 455
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
Waldherr, C., Pless, M., Maëcke, H. R., Schumacher, T., Crazzolara, A., Nitzsche, E. U., Haldemann, A. R., & Mueller‐Brand, J. (2002) · PubMed · Cited by 445
Gupta, S., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., et al. (2005) · Cancer · doi:10.1002/cncr.21389 · Cited by 433
Yttrium-90 DOTATOC: first clinical results
Otte, A., Herrmann, R., Heppeler, A., Behe, M., Jermann, E., Powell, P., Maecke, H. R., & Muller, J. (1999) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050476 · Cited by 420
Waldherr, C., Pless, M., Maecke, H. R., Haldemann, A., & Mueller-Brand, J. (2001) · Annals of Oncology · doi:10.1023/a:1011160913619 · Cited by 396
Incidence trends and risk factors of carcinoid tumors: A nationwide epidemiologic study from Sweden
Hemminki, K., & Li, X. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8<2204::aid-cncr1564>3.0.co;2-r · Cited by 363
Sun, W., Lipsitz, S., Catalano, P., Mailliard, J. A., & Haller, D. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.616 · Cited by 357
Valkema, R., Pauwels, S. A., Kvols, L. K., Kwekkeboom, D. J., Jamar, F., de Jong, M., Barone, R., Walrand, S., Kooij, P. P. M., Bakker, W. H., et al. (2005) · PubMed · Cited by 332
Self-citationValkema, R., Pauwels, S., Kvols, L. K., Barone, R., Jamar, F., Bakker, W. H., Kwekkeboom, D. J., Bouterfa, H., & Krenning, E. P. (2006) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2006.01.001 · Cited by 313
Self-citationBodei, L., Cremonesi, M., Zoboli, S., Grana, C., Bartolomei, M., Rocca, P., Caracciolo, M., Mäcke, H. R., Chinol, M., & Paganelli, G. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1023-y · Cited by 305
Epidemiology and survival in patients with carcinoid disease in the Netherlands
Quaedvlieg, P. F. H. J., Visser, O., Lamers, C. B. H. W., Janssen-Heijen, M. L. G., & Taal, B. G. (2001) · Annals of Oncology · doi:10.1023/a:1012272314550 · Cited by 260
Mazzaglia, P. J., Berber, E., Milas, M., & Siperstein, A. E. (2007) · Surgery · doi:10.1016/j.surg.2007.01.036 · Cited by 256
Bajetta, E., Catena, L., Procopio, G., De Dosso, S., Bichisao, E., Ferrari, L., Martinetti, A., Platania, M., Verzoni, E., Formisano, B., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0306-6 · Cited by 240
Janson, E. T., & Öberg, K. (1993) · Acta Oncologica · doi:10.3109/02841869309083916 · Cited by 204
Cheng, P. N. M., & Saltz, L. B. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990915)86:6<944::aid-cncr8>3.0.co;2-p · Cited by 199
The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
Ducreux, M. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02003-7 · Cited by 196
Esser, J. P., Krenning, E. P., Teunissen, J. J. M., Kooij, P. P. M., van Gameren, A. L. H., Bakker, W. H., & Kwekkeboom, D. J. (2006) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-006-0172-9 · Cited by 179
Self-citationHo, A. S., Picus, J., Darcy, M. D., Tan, B., Gould, J. E., Pilgram, T. K., & Brown, D. B. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.06.0933 · Cited by 158
Lepage, C., Bouvier, A., Phelip, J. M., et al. (2004) · Gut · doi:10.1136/gut.2003.026401 · Cited by 146
A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors
Ansell, S. M., Pitot, H. C., Burch, P. A., Kvols, L. K., Mahoney, M. R., & Rubin, J. (2001) · Cancer · doi:10.1002/1097-0142(20010415)91:8<1543::aid-cncr1163>3.0.co;2-n · Cited by 107
Marrache, F., Vullierme, M., Roy, C., Assoued, Y. E., Couvelard, A., O’Toole, D., Mitry, E., Hentic, O., Hammel, P. R., Lévy, P., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603526 · Cited by 103
The epidemiology of carcinoid tumours in England and Scotland
Newton, J. N., Swerdlow, A. J., Silva, I. D. S., Vessey, M., Grahame‐Smith, D., Primatesta, P., & Reynolds, D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.424 · Cited by 102
Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–97
Levi, F., Te, V.-C., Randimbison, L., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1394 · Cited by 90
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid
Bukowski, R. M., Tangen, C. M., Peterson, R. F., Fleming, T. R., Taylor, S. A., Rinehart, J. J., Eyre, H. J., Rivkin, S. E., Macdonald, J. S., & A Southwest Oncology Group Study (1994) · Cancer · Cited by 90
Alkaline Phosphatase Predicts Survival in Patients with Metastatic Neuroendocrine Tumors
Clancy, T. E., Sengupta, T. P., Paulus, J. K., Ahmed, F., Duh, M. S., & Kulke, M. H. (2006) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9345-4 · Cited by 72
Gastroenteropancreatic Endocrine Tumours: Effect of Sandostatin® on Tumour Growth
Arnold, R., Benning, R., Neuhaus, C., et al. (2009) · Digestion · doi:10.1159/000201081 · Cited by 65
Ablative Therapies for Liver Metastases of Gastroenteropancreatic Endocrine Tumors
Ruszniewski, P. B., & O’Toole, D. (2004) · Neuroendocrinology · doi:10.1159/000080746 · Cited by 46
Andreyev, J. N., Scott-Mackie, P., Cunningham, D., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.6.1486 · Cited by 46
Treatment of metastasized midgut carcinoids with dacarbazine.
Ritzel, U., Leonhardt, U., Stöckmann, F., et al. (1995) · PubMed · Cited by 43
Kidney failure after treatment with 90Y-DOTATOC
Schumacher, T., Waldherr, C., Mueller‐Brand, J., et al. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-001-0720-2 · Cited by 24
Neijt, J. P., Lacave, A. J., Splinter, T. A. W., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.21 · Cited by 22
Cited by
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Self-citationRinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Gastroenteropancreatic neuroendocrine tumours
Modlin, I. M., Oberg, K., Chung, D. C., Jensen, R. T., de Herder, W. W., Thakker, R. V., Caplin, M., Delle Fave, G., Kaltsas, G. A., Krenning, E. P., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70410-2 · Cited by 1,748
Self-citationFalconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Self-citation
Metadata
- Authors
- Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-05-01
- Volume
- 26
- Issue
- 13
- Pages
- 2124-2130
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2125398839
- Cited by
- 1,456
- References
- 36
- FWCI
- 46.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.